Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524594 | 0.98 | SHBG (0.39) | SHBGCYP1A2TSHREPHX1SIGMAR1 | |
| SCHEMBL9207424 | 0.98 | SHBG (0.34) | SHBGTSHREPHX1SIGMAR1 | |
| SCHEMBL9204484 | 0.98 | SHBG (0.34) | SHBGTSHREPHX1SIGMAR1 | |
| SCHEMBL10472499 | 0.96 | SHBG (0.38) | SHBGCYP1A2TSHREPHX1SIGMAR1 | |
| SCHEMBL9210781 | 0.96 | SHBG (0.38) | SHBGCYP1A2TSHREPHX1SIGMAR1 | |
| SCHEMBL9209181 | 0.96 | SHBG (0.38) | SHBGCYP1A2TSHREPHX1SIGMAR1 | |
| SCHEMBL9205067 | 0.94 | SHBG (0.37) | SHBGCYP1A2SIGMAR1 | |
| SCHEMBL1524470 | 0.90 | LMNA (0.35) | OPRM1TSHR | |
| SCHEMBL11677040 | 0.85 | SHBG (0.44) | SHBGCYP1A2TSHREPHX1SIGMAR1 | |
| SCHEMBL29322013 | 0.85 | SHBG (0.39) | SHBGCYP1A2TSHREPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109883-A1 | Anti-Tumor Compositions and Methods | EVRYS BIO, LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230416241-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2023-12-28 | — | — | US | disclosed |
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-11358961-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| EP-2763533-B1 | TRIAZOLYL PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-105777776-B | Inhibitors of protein tyrosine kinase activity | 梅特希尔基因公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| EP-2542076-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2004048393-A2 | NOVEL INHIBITORS OF β-LACTAMASE | METHYLGENE, INC. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | METHYLGENE, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004035571-A1 | SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035525-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2004-04-29 | — | — | WO | disclosed |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-20030225112-A1 | Inhibitors to tubulin polymerization | RIGEL PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003070241-A1 | INHIBITORS OF TUBULIN POLYMERIZATION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416241-A1 | Broad Spectrum Antiviral Compositions and Methods | IRF3, MAVS, ZC3HAV1 | SHBG 4373/4885CYP1A2 3233/4885OPRM1 4832/4885 |
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | SHBG 4373/4885CYP1A2 3233/4885OPRM1 4832/4885 |
| US-11358961-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | SHBG 3533/4885CYP1A2 4826/4885OPRM1 4843/4885 |
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | SHBG 4421/4885CYP1A2 4430/4885OPRM1 4869/4885 |
| US-20030225112-A1 | Inhibitors to tubulin polymerization | TUBB3, TUBB1, TUBB | SHBG 4467/4885CYP1A2 4057/4885OPRM1 4843/4885 |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, COASY | SHBG 1462/4885CYP1A2 224/4885OPRM1 2020/4885 |
| US-20240109883-A1 | Anti-Tumor Compositions and Methods | DDX5, IRF3, TP53 | SHBG 3510/4885CYP1A2 4146/4885OPRM1 4412/4885 |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | SHBG 2036/4885CYP1A2 4785/4885OPRM1 4775/4885 |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | MAVS, IRF3, ZC3HAV1 | SHBG 4317/4885CYP1A2 3882/4885OPRM1 4558/4885 |
| US-20220135556-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | SHBG 3533/4885CYP1A2 4826/4885OPRM1 4843/4885 |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | LSS, MGAM, COASY | SHBG 1450/4885CYP1A2 167/4885OPRM1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.